Novartis, CH0012005267

Novartis stock: October 23 investor call ahead of the Xetra open

Published on 10/20/2026 at 07:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis also lists third-quarter results for October 27, 2026. At Lang & Schwarz the stock trades pre-market at EUR 134.46 on October 20, 2026.

Investor dates remain ahead

The Remibrutinib in MS investor call is scheduled for October 23, 2026.
Novartis lists third-quarter results for October 27, 2026.
Novartis stock trades pre-market at EUR 134.46 at 7:45 a.m. CEST at Lang & Schwarz on October 20, 2026.

Forscherin in weißem Kittel pipettiert in Reagenzglas im sterilen Pharmalabor — Novartis AG CH0012005267 – Forscherin pipettiert präzise in steriler Pharmalaborumgebung mit Reagenzgläsern, Illustration mit AI erstellt.

Novartis lists a Remibrutinib in MS investor call for October 23, 2026, according to the company's investor-relations page. At Lang & Schwarz, Novartis stock trades pre-market at EUR 134.46 at 7:45 a.m. CEST on October 20, 2026.

Upcoming investor dates

The webcast is listed for October 23, 2026, with the company also scheduling its third-quarter 2026 results for October 27, 2026. The dates and event details are published by Novartis.

Before the Xetra open

The 7:45 a.m. CEST indication from Lang & Schwarz is EUR 134.46. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.

Pharmaceutical products and events

Novartis designs, manufactures and markets pharmaceutical products, according to the company profile published by MarketScreener. The next listed company dates are October 23, 2026, and October 27, 2026.

Market context: Market report SMI.

More news and analysis on Novartis stock